As compared to Gilead’s drug Atripla that is leading the market, a drug from GlaxoSmithKline and its Japanese partner Shionogi has proved better. It is once daily drug and it went through a late-stage clinical trial.

India's Bangalore-based Biocon has decided that it will be divesting its stake in the German drug distributor, AxiCorp GmbH. Some three years back it had taken up controlling stake in the company and now it will be selling the shares to the minority shareholders of the company.